Antitumor Activity, Pharmacology and Clinical Trials of Elliptinium (NSC 264-137)
Ellipticine and some of its derivatives are naturally occuring alkaloids found in plants of the Apocynaceae family. The antitumoral activities were described in 1967 by Dalton et al.(1) and later confirmed by Mathe et al. who reported the antitumor activity of 9-methoxy-ellipticine in patients with acute myeloblastic leukemia. The finding of drug-related side-effects such as hemolysis and nervous toxicity (3,4) prompted an intensive search for new derivatives at the Institut Gustave-Roussy in Villejuif, France.
KeywordsAntitumor Drug Acute Myeloblastic Leukemia Glutathione Conjugate Mixed Function Oxygenase Hyperplastic Alveolar Nodule
Unable to display preview. Download preview PDF.
- 3.E. H. Herman, D. P. Chadwick, and R. M. Mhatre, Comparison of the acute hemolytic and cardiovascular action of ellipticine (NSC 71795) and some ellipticine analogs, Cancer Chemother., 58: 637 (1974).Google Scholar
- 4.R. H. Liss, and C. J. Kensler, Radioautographic methods for physiologic, disposition and toxicology studies, in: “Advances in modern toxicology; new concepts in safety evaluation”. Hemisphere Publishing Corp., Washington D.C. (1976).Google Scholar
- 6.J. B. LePecq, C. Gosse, N. Dat-Xuong, S. Cros, and C. Paoletti, Anti-tumoral activity of 9-hydroxy ellipticine (NSC 210717) on L1210 mice leukemia, Cancer Res., 36: 3067 (1976).Google Scholar
- 7.C. Paoletti, J. B. LePecq, N. Dat-Xuong, P. Lesca, and P. Lecointe, New anticancer derivatives in the ellipticine series, Curr. Chemother., 1195 (1978).Google Scholar
- 15.E. Garcia-Giralt, and A. Macieira-Coelho, Methoxy-9-ellipticine. Analysis in vitro of the mechanism of action, Eur. J. Clin. Biol. Res., 15: 539 (1970).Google Scholar
- 16.C. Paoletti, J. B. LePecq, N. Dat-Xuong, P. Juret, H. Garnier, J.L. Amiel, and J. Rouesse, Antitumor activity, pharmacology and toxicity of ellipticines, ellipticinium and 9-hydroxy derivatives: preliminary clinical trials of 2-methyl-9-hydroxy ellipticinium (NSC 264–137). Recent Results, Cancer Res., 74: 107 (1984).CrossRefGoogle Scholar
- 19.L. A. Zwelling, S. Michaels, L. C. Ericson, L. C. Ungerleider, R.S. Nichols, and K. W. Kohn, Protein-associated DNA strand breaks in L1210 cells treated with the DNA intercalating agents, 4’(9-acridinylamino) methanesulfon-m-anisidine (m-AMSA) and adriamycin, Biochemistry, 20: 6553 (1981).PubMedCrossRefGoogle Scholar
- 25.M. Majetouh, B. Montsarrat, R. C. Rao, B. Meunier, and C. Paoletti, Identification of the glucuronide and glutathione conjugates of the antitumor drug 2N-methyl-9-hydroxyelliptinium acetate (Celiptium), Drug Metab. Dise., 12: 111 (1984).Google Scholar
- 26.L. W. Oberley, and C. R. Buettner, Role of superoxide dismutase in cancer, Cancer Res., 39: 1141 (1980).Google Scholar
- 30.J. L. Amiel, J. Rouesse, J. P. Droz, P. Caille, J. P. Travagli, C. Theodore, T. Le Chevalier, J. P. Ducret, J. M. Bidard, H. Garnier, and C. Paoletti, Chimotherapie des cancers du rein, metastases par le N-methylhydroxyellipticinium (NHME), Nouv. Presse Med., 10: 1504 (1981).Google Scholar